Atyr PHARMA (ATYR) Competitors $3.61 -0.14 (-3.73%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATYR vs. SPRY, SNDX, COLL, ELVN, BCYC, NTLA, RCKT, ZYME, ADPT, and GYREShould you be buying Atyr PHARMA stock or one of its competitors? The main competitors of Atyr PHARMA include ARS Pharmaceuticals (SPRY), Syndax Pharmaceuticals (SNDX), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Bicycle Therapeutics (BCYC), Intellia Therapeutics (NTLA), Rocket Pharmaceuticals (RCKT), Zymeworks (ZYME), Adaptive Biotechnologies (ADPT), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Atyr PHARMA vs. ARS Pharmaceuticals Syndax Pharmaceuticals Collegium Pharmaceutical Enliven Therapeutics Bicycle Therapeutics Intellia Therapeutics Rocket Pharmaceuticals Zymeworks Adaptive Biotechnologies Gyre Therapeutics Atyr PHARMA (NASDAQ:ATYR) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation. Does the MarketBeat Community believe in ATYR or SPRY? ARS Pharmaceuticals received 11 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 84.00% of users gave ARS Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAtyr PHARMAOutperform Votes10100.00% Underperform VotesNo VotesARS PharmaceuticalsOutperform Votes2184.00% Underperform Votes416.00% Is ATYR or SPRY more profitable? ARS Pharmaceuticals' return on equity of -22.56% beat Atyr PHARMA's return on equity.Company Net Margins Return on Equity Return on Assets Atyr PHARMAN/A -79.44% -59.16% ARS Pharmaceuticals N/A -22.56%-21.82% Which has more volatility and risk, ATYR or SPRY? Atyr PHARMA has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Does the media prefer ATYR or SPRY? In the previous week, ARS Pharmaceuticals had 10 more articles in the media than Atyr PHARMA. MarketBeat recorded 17 mentions for ARS Pharmaceuticals and 7 mentions for Atyr PHARMA. Atyr PHARMA's average media sentiment score of 0.95 beat ARS Pharmaceuticals' score of 0.60 indicating that Atyr PHARMA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atyr PHARMA 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of ATYR or SPRY? 61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by insiders. Comparatively, 40.1% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation and earnings, ATYR or SPRY? Atyr PHARMA has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Atyr PHARMA, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtyr PHARMA$350K865.78-$50.39M-$0.94-3.84ARS Pharmaceuticals$30K40,718.42-$54.37M-$0.51-24.65 Do analysts prefer ATYR or SPRY? Atyr PHARMA currently has a consensus target price of $19.25, suggesting a potential upside of 433.24%. ARS Pharmaceuticals has a consensus target price of $26.00, suggesting a potential upside of 106.84%. Given Atyr PHARMA's higher probable upside, research analysts plainly believe Atyr PHARMA is more favorable than ARS Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 SummaryARS Pharmaceuticals beats Atyr PHARMA on 10 of the 18 factors compared between the two stocks. Get Atyr PHARMA News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATYR vs. The Competition Export to ExcelMetricAtyr PHARMABiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$296.32M$2.95B$5.21B$8.93BDividend YieldN/A1.94%5.13%4.04%P/E Ratio-3.8445.5689.8017.35Price / Sales865.78263.271,248.2377.32Price / CashN/A192.9043.8235.97Price / Book2.343.965.324.79Net Income-$50.39M-$41.02M$122.69M$225.00M7 Day Performance2.27%-1.69%-0.17%1.52%1 Month Performance14.60%-0.11%3.49%4.88%1 Year PerformanceN/A-2.20%25.79%20.12% Atyr PHARMA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATYRAtyr PHARMA2.8938 of 5 stars$3.61-3.7%$19.25+433.2%N/A$296.32M$350,000.00-3.8453Short Interest ↑SPRYARS Pharmaceuticals3.0316 of 5 stars$11.26+0.2%$24.50+117.6%+106.7%$1.09B$2.57M-22.0890Analyst ForecastSNDXSyndax Pharmaceuticals3.7242 of 5 stars$12.80-2.4%$36.20+182.8%-38.6%$1.09B$16M-3.53110Short Interest ↑News CoverageCOLLCollegium Pharmaceutical4.2901 of 5 stars$33.79+2.7%$43.80+29.6%+1.5%$1.09B$599.25M14.56210Insider TradeELVNEnliven Therapeutics2.2946 of 5 stars$22.07+1.5%$38.25+73.3%+67.6%$1.08BN/A-11.6250BCYCBicycle Therapeutics3.2885 of 5 stars$15.16+13.9%$34.50+127.6%-24.8%$1.05B$36.90M-4.61240Short Interest ↑Analyst RevisionGap UpNTLAIntellia Therapeutics4.4861 of 5 stars$10.05-1.5%$51.56+413.1%-62.4%$1.02B$43.09M-1.85600Analyst ForecastNews CoverageRCKTRocket Pharmaceuticals4.5012 of 5 stars$10.73-3.7%$47.27+340.6%-60.6%$978.12MN/A-3.90240News CoverageZYMEZymeworks3.8142 of 5 stars$13.96+5.6%$19.17+37.3%+40.8%$961.54M$62.20M-9.31290Insider TradePositive NewsADPTAdaptive Biotechnologies2.6215 of 5 stars$6.46-0.6%$6.75+4.5%+67.3%$953.36M$177.28M-4.82790News CoverageGYREGyre Therapeutics0.3144 of 5 stars$9.99flatN/A-47.4%$934.28M$105.03M0.0040Short Interest ↑News Coverage Related Companies and Tools Related Companies ARS Pharmaceuticals Alternatives Syndax Pharmaceuticals Alternatives Collegium Pharmaceutical Alternatives Enliven Therapeutics Alternatives Bicycle Therapeutics Alternatives Intellia Therapeutics Alternatives Rocket Pharmaceuticals Alternatives Zymeworks Alternatives Adaptive Biotechnologies Alternatives Gyre Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATYR) was last updated on 1/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atyr PHARMA INC Please log in to your account or sign up in order to add this asset to your watchlist. Share Atyr PHARMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATYR Stock Alerts